KALA BIO, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.0M
- Price
- $0.36
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.10%
- Volume
- 615.9K
About
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Quick stats
Shares outstanding19.3M
Computed float19.2M
Float / shares99.5%
Cash runway (months)0.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001479419
Websitehttps://www.kalarx.com
AI Summary
AI-generated1/10
standardbullishm and a
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
KALA Bio signed a non-binding LOI to acquire 100% of a U.S.-based MSO supporting a 50-state telehealth platform for approximately $15 million in cash and stock.
The Target generated about $12.7 million in trailing-twelve-month revenue through August 2026, is cash-flow positive, and has served more than 90,000 clients since 2023, focused on GLP-1 weight management, hormone health, longevity and sexual wellness.
A 45-day diligence period concludes in November 2026, with definitive agreements and closing targeted for late 2026 or early 2027; the deal faces stockholder, Nasdaq and pharmacy-license approvals.
KALA sees the Target as a direct-to-consumer channel for its Virotek genetic testing and a fit with its Researgency.ai platform, but the Target's financials are unaudited and management-provided.
Red flags
- LOI is non-binding; no assurance definitive agreements will be executed
- Target financials are unaudited and provided by Target management without independent verification
- Stock consideration may dilute existing holders and requires Nasdaq Listing Rule approvals and possible stockholder vote
- Reliance on compounded GLP-1 products carries FDA/regulatory enforcement risk (503A/503B) and branded-manufacturer litigation risk
- Company discloses limited cash resources and going-concern risk; Nasdaq listing compliance risk